Bioniche follows good FY, with promising new deal

Guest Contributor
September 22, 2009

Bellville ON-based Bioniche Life Sciences Inc has released its FY09 year-end results that show significant improvement in revenue generation as sales from its animal health products continue to rise. Sales for FY09 were up 21% to $33.3 million while gross R&D expenses declined 16.7% to $13.3 million. The majority of R&D was devoted to Phase III clinical trials for Bioniche's bladder cancer therapy and E.coli O157 cattle vaccine development program. Subsequent the year-end, Bioniche signed an agreement with Endo Pharmaceuticals Inc to market its bladder cancer drug in the US with an option for global rights. The agreement came with a US$20-million milestone payment….


Other News






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.